Precision BioSciences advances hepatitis B gene-editing therapy PBGENE-HBV to Phase 2

PUBT · 20h ago
Precision BioSciences advances hepatitis B gene-editing therapy PBGENE-HBV to Phase 2
  • Precision BioSciences is advancing hepatitis B gene-editing therapy PBGENE-HBV into Phase 2 following encouraging Phase 1 results.
  • Treatment showed durable suppression of a viral marker and biopsy evidence of reductions in the persistent viral reservoir.
  • Safety was manageable, with no dose-limiting toxicities; no serious adverse events occurred at the selected Phase 2 dose.
  • Results will be presented November 8, 2026, at AASLD's The Liver Meeting.
  • Phase 2 dosing is expected in the first quarter of 2027, with initial open-label data anticipated in the second half.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050700BIZWIRE_USPR_____20261105_BW643191) on November 05, 2026, and is solely responsible for the information contained therein.